Literature DB >> 9619855

Production and regulation of interleukin-11 by breast cancer cells.

M Lacroix1, B Siwek, P J Marie, J J Body.   

Abstract

We have studied the production of interleukin-11 (Il-11) in 13 breast cancer cell (BCC) lines. Two of these cell lines (MDA-MB-231 and Hs578T) expressed the cytokine at both the protein and mRNA levels. Il-11 did not modulate the growth of five BCC lines examined, including the two cytokine-producing BCC lines. The production of Il-11 was increased by transforming growth factor-beta1 in a dose-dependent manner with a rapid (2 h) and transient (24 h) mRNA induction, but not by epidermal growth factor, insulin-like growth factor-I and -II, basic fibroblast growth factor, platelet-derived growth factor or parathyroid hormone. The cyclic AMP inducer, forskolin, and the activator of protein kinase C, phorbol 12-myristate 13-acetate, also stimulated the production of Il-11. Besides Il-11, MDA-MB-231 and Hs578T were the only BCC lines to produce interleukin-6 (Il-6) protein and mRNA. Since Il-11 and Il-6 are potent stimulators of osteoclast development and bone is a major source of TGF-beta1, our data suggest that Il-11, together with Il-6, contributes to the high bone destructive capacity of MDA-MB-231 cells and could play a role in breast cancer-induced osteolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619855     DOI: 10.1016/s0304-3835(97)00542-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  The production of interleukin-11 and decidualization are compromised in endometrial stromal cells derived from patients with infertility.

Authors:  Natalia Karpovich; Petra Klemmt; Jung Hye Hwang; J Enda McVeigh; John K Heath; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Yuzo Furuya; Remon Nishio; Akira Junicho; Osamu Nagakawa; Hideki Fuse
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Authors:  Barbara Onnis; Nicole Fer; Annamaria Rapisarda; Victor S Perez; Giovanni Melillo
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

5.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.

Authors:  C L Campbell; Z Jiang; D M Savarese; T M Savarese
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  A novel orthotopic model of breast cancer metastasis to bone.

Authors:  M Lelekakis; J M Moseley; T J Martin; D Hards; E Williams; P Ho; D Lowen; J Javni; F R Miller; J Slavin; R L Anderson
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

7.  Preeclampsia-related increase of interleukin-11 expression in human decidual cells.

Authors:  Murat Basar; Chih-Feng Yen; Lynn F Buchwalder; William Murk; S Joseph Huang; Karl Godlewski; Erdogan Kocamaz; Oktay Arda; Frederick Schatz; Charles J Lockwood; Umit A Kayisli
Journal:  Reproduction       Date:  2010-07-28       Impact factor: 3.906

8.  Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway.

Authors:  Li Ren; Xia Wang; Zuoliang Dong; Jun Liu; Shiwu Zhang
Journal:  Med Oncol       Date:  2013-06-28       Impact factor: 3.064

Review 9.  Bioengineering embryonic stem cell microenvironments for the study of breast cancer.

Authors:  Nurazhani Abdul Raof; Bridget M Mooney; Yubing Xie
Journal:  Int J Mol Sci       Date:  2011-11-08       Impact factor: 5.923

10.  IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.

Authors:  Erin M McCoy; Huixian Hong; Hawley C Pruitt; Xu Feng
Journal:  BMC Cancer       Date:  2013-01-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.